Anomalous patterns of nitroimidazole binding adjacent to necrosis in human glioma xenografts: possible role of decreased oxygen consumption. by Parliament, M. B. et al.
British Journal ofCancer(1997) 75(3), 311-318
( 1997 Cancer Research Campaign
Anomalous patterns of nitroimidazole binding adjacent
to necrosis in human glioma xenografts: possible role of
decreased oxygen consumption
MB Parliament1, AJ Franko1, MJ Allalunis-Turner1, BW Mielke2, CL Santos1, BG Wolokoff1 and JR Mercer3
'Departments of Radiation Oncology and Radiobiology, Cross Cancer Institute, 11560 University Avenue, Edmonton, Alberta, Canada T6G 1Z2; 2Department of
Laboratory Medicine and Pathology, WC MacKenzie Health Sciences Centre, 8440-112 Street, Edmonton, Alberta, Canada T6G 2B7; 3Department of
Pharmacy, Faculty of Medicine, University of Alberta, Edmonton, Alberta, Canada T6G 2N8
Summary In contrast to reports of extensive hypoxia in human gliomas in situ measured by P02 histography, non-invasive methods of
assessing glioma oxygenation, including nitroimidazole binding, have yielded surprisingly contradictory results. In order to investigate the
relationship of necrosis, hypoxia, nitroreductase activity and cellular respiration in human gliomas, subcutaneous models using the human
glioma cell lines M059K, M006 and M01Ob were developed in the murine SCID host. Intracranial growth of the M006 line was achieved in nude
rats. The nitroreductive capacity of glioma cell lines was assessed and found to be similar to transplanted tumours previously reported in the
literature. This suggests that if substantial numbers of viable hypoxic cells were present in situ in gliomas, then nitroimidazole-binding
techniques should be capable of identifying them. Inter-tumour variability in the amount of necrosis was seen. M006 xenografts growing in
subcutaneous and intracranial sites revealed extensive necrotic regions histologically, some of which were surrounded by cells labelled heavily
for [3H]misonidazole, while other areas were lightly labelled. Similar binding patterns were seen for subcutaneous M059K tumours, while
subcutaneous M01Ob tumours display necroses of which almost all were surrounded by heavily labelled cells. The oxygen consumption rates
of tumour cell lines grown in vivo, in which venous P02 concentrations are of the order of 2-5%, were two to sevenfold less than those of the
same lines grown as monolayers in vitro under oxygen concentrations of 18%. We postulate that glioma cell lines behave as 'oxygen
conformers', in that their rate of oxygen consumption appears to vary with the availability of oxygen. Together with the misonidazole-binding
data, the results in this glioma tumour model are consistent with coordinate inhibition ordown-regulation of respiration under moderate hypoxia.
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Malignant gliomas are highly cellular tumours which normally
contain necrosis (Nelson J et al, 1983; Wilden et al, 1987) and
which are commonly assumed to contain substantial numbers of
hypoxic cells. Almost all macroscopic transplanted tumours in
rodents contain viable hypoxic cells, which are a major cause of
radioresistance (Moulder and Rockwell, 1984; Rockwell and
Moulder, 1990). However, the incidence and natural history of
hypoxia in human brain tumours before and during radiotherapy is
poorly understood. The benefit of the use of hypoxic cell radio-
sensitizers with radiotherapy for gliomas was has been reported
for metronidazole (Urtasun et al, 1976) but not for misonidazole
(Bleehen et al, 1981; Nelson D et al, 1983; Green et al, 1984).
Attempts to identify tumour hypoxia in human gliomas using
nitroimidazole adduct techniques have yielded unexpected results.
No evidence for hypoxia was obtained in a series of human
glioblastomas imaged with [1231]iodoazomycin arabinoside
(['231]IAZA) despite the fact that avidity for this compound was
noted in 75% of the brain metastases studied and in 40% of
extracranial tumours (Groshar et al, 1993; Urtasun et al, 1996).
['tF]Fluoromisonidazole imaging data in glioma are limited,
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however increased fluoromisonidazole uptake relative to plasma
has arguably been demonstrated in only one of three patients
reported (Valk et al, 1992).
Positron emission tomographic (PET) studies on the metabolic
use of oxygen in breast and brain tumours in situ have been
reported (Ito et al, 1982; Lammertsma et al, 1985; Brooks, 1990).
In these studies, the tumour oxygen extraction ratio (OXR) was
used as an indirect indicator of hypoxia, assuming that hypoxic
tumour tissue would extract a greater fraction of oxygen from
capillary blood than aerobic tumour or normal tissue. These
studies demonstrated elevated tumour OXR relative to normal
tissue in individual breast tumours; however, elevated OXRs were
not seen in malignant gliomas, and indeed the tumour OXR was
lower than in normal brain, consistent with diminished oxygen
consumption in the tumours. These imaging techniques rely on the
averaging ofsignals from relatively large volumes oftissue, hence
the presence of smaller volumes of hypoxic cells within microre-
gions that maximally extract available oxygen cannot be excluded.
However, ifboth nitroimidazole binding and '50-PET data sets are
correct, they predict that the majority of gliomas do not contain
large regions of viable, chronically hypoxic cells.
In contrast, pO2 histography in human gliomas in situ during
anaesthesia has suggested extensive hypoxia in the lesions
themselves and in peritumoral oedema (Cruickshank and
Rampling, 1994a, b; Rampling et al, 1994). These data appear to
support the clinical trials currently underway testing the thera-
peutic role of hypoxic cytotoxins in malignant gliomas. However,
311312 MB Parliament etal
electrodes are unable to distinguish between viable tumour tissue
and acellular necrosis, and the effect of anaesthesia upon the
oxygen electrode measurements in the brain remains to be defined.
These conflicting lines of evidence lead us to develop tumour
models which could be used to examine the anomalous nitroimida-
zole-binding characteristics and oxygenation status of gliomas.
Our objectives were to test two hypotheses for the failure of
[123111AZA to detect hypoxic regions in human gliomas, namely
(1) inadequate drug delivery or intracellular uptake and (2) altered
kinetics of nitroimidazole bioreduction by glioma reductases. It
is recognized that, particularly in deeper portions of the tumour
adjacent to necrosis, the vasculature of large intact gliomas is
disrupted (Krauseneck and Muller, 1995). For this reason, inade-
quate IAZA transport across the blood-brain barrier to the putative
hypoxic glioma cells was considered the least probable explana-
tion. In this report, we show that human glioma cell lines growing
as subcutaneous or intracranial xenografts in immune-deficient
rodents variably display evidence of necrosis; some necroses are
surrounded by cells which are heavily labelled by [1251I]IAZA or
the prototypic hypoxia marker [3H]misonidazole, while others
unexpectedly are not. In experiments testing the kinetics of
nitroimidazole bioreduction in vitro, results consistent with the
kinetics of this process in murine and other human tumours were
obtained. These results suggest an additional hypothesis i.e. under
conditions of constrained oxygen supply, oxygen consumption is
down-regulated and development of necrosis (at least in some
microregions) may occur through the depletion of substrates other
than oxygen, perhaps because of an inability to meet the demands
ofaerobic glycolysis (Kormblith et al, 1984; Wise et al, 1984). This
report describes the in vitro and in vivo tumour systems used to
test these hypotheses.
MATERIALS AND METHODS
Cell lines
The glioma cell lines used in these studies were derived from
portions of diagnostic biopsies obtained from patients with
glioblastoma and were supplied by Dr RS Day III. The procedures
used to dissociate the tumour specimens and to establish the cell
lines have been previously published (Allalunis-Tumer et al,
1991). The M0059K cell line was derived from the biopsy of a
grade IV astrocytoma with focal necrosis, vascular proliferation
and occasional gemistocytes. The M006 line was derived from a
grade IV astrocytoma with a relatively low mitotic index, promi-
nent vascular endothelial proliferation and extensive necrosis. The
MOlOb line was derived from an anaplastic astrocytoma showing
moderate pleomorphism, frequent mitoses, vascular endothelial
proliferation but no giant cells or necrosis. Monolayer cultures
were prepared using M006, M059K and MOlOb cells thawed from
frozen stock. The cultures were maintained in Dulbecco's modi-
fied Eagle Medium (DMEM)-F12 with 10% fetal calf serum
(Gibco, Grand Island, NY, USA).
Xenografts
All animal experiments were performed according to guidelines
for the use of animals in research established by the Canadian
Council for Animal Care. SCID mice and nude rats used for
xenograft transplantation were housed in filter-topped cages in a
clean barrier facility and fed autoclaved rodent chow ad libitum.
C.B. 17 SCID mice obtained from Jackson (BarHarbor, ME, USA)
and bred at the Health Sciences Laboratory Animal Services,
University of Alberta, Canada, were used for the M0059J, M006
and MOOlOb lines. C.B.-17/IcrCrl-scid mice from Charles River
(St Constant, Quebec) were used for sublines (MOO59KX and
M006X). Tumours were initiated in mice 6 to 10 weeks of age by
subcutaneous injection of 106 to 107 cells in both flanks. Tumour
growth was monitored by weekly or biweekly calliper measure-
ments taken in three orthogonal directions. Tac:N:NIH-rnufDF
nude rats were obtained from Taconic (Germantown, NY, USA)
and received 5 Gy whole-body irradiation (137Cs, Shepherd Mark I,
Shepherd and Associates, San Fernando, CA, USA) at 5 weeks of
age. The next day, 2.5 x 104 M006 tumour cells in 0.05 ml ofsaline
were injected at a single intracerebral site over a 5-min period. The
site was 3 mm below the surface of the brain through a burr hole
located 2 mm posterior and 3 mm lateral to the bregma.
[3H]Misonidazole, with a specific activity of 15.6 mCi mg-'
(580 MBq mg-') was synthesized following a published procedure
(Born and Smith, 1983). It was diluted with cold misonidazole to a
final specific activity of between 820 and 3700 tCi mg-' for
labelling tumour-bearing mice and rats in vivo and tumour frag-
ments in vitro. A final concentration of 50 gM misonidazole
was used both in vitro and as a calculated initial whole-body
concentration in vivo. 1-(5-['251]Iodo-5-deoxy-4-D-arabinofura-
nosyl)-2-nitroimidazole, ([1251]IAZA), was synthesized as follows:
['251]sodium iodide (Amersham Canada) as adry residue in a small
v-vial was treated with 0.6 mg ofIAZA and 3.3 mg ofpivalic acid
in methanol. The solvent was removed at 40°C under a stream
of nitrogen gas. The residue was heated at 780C for 75 min to
effect the exchange labelling. The crude product was purified by
preparative liquid chromatography on a reverse-phase column
(Whatman). The final product had a specific activity of 94 ,uCi
mg-' (3.5 MBq mg-') and was injected into tumour-bearing mice at
an initial whole-body concentration of 84gM.
Mice were injected with nitroimidazoles when tumour volumes
equalled 100-300 mm3. The required quantity of drug was
dissolved in saline, and 0.2 ml was injected intraperitoneally three
times at hourly intervals. The mice were euthanized 1 h after the
last injection, and the tumours were excised and cut into two or
four pieces, depending on the initial size ofthe tumour. Halfofthe
pieces were fixed in 10% buffered formalin for 24 h at 4°C, then
for 2-6 days at room temperature, and the remaining pieces were
fixed in 100% ethanol for 24 h at4°C. The rats bearing intracranial
tumours were labelled with [3H]misonidazole as soon as any indi-
cations of tumour development were observed (unusual eye or
eyelid motion, abnormal posture, lethargy, balance problems,
partial paralysis of any limb). Two intraperitoneal injections were
given at 1.5 h intervals (hourly injections were unnecessary
because ofthe longer half-life ofmisonidazole in the blood ofrats)
(Franko et al, 1992). The rats were euthanized 1.5 h after the last
injection, and the tumours were fixed in formalin as above.
The tumours were embedded in wax, sectioned at 5 ,um and
placed on slides which, in the case of the ethanol-fixed portions,
had been coated with poly-L-lysine. The sections were dewaxed
with xylene, rehydrated and dipped in NTB-2 Nuclear Track
Emulsion (Kodak, Rochester, NY, USA) for autoradiography. The
emulsion was exposed for 1 to 6 weeks, developed and the tissues
were stained with haematoxylin and eosin.
Nitroreductive activity ofglioma tissue in vitro was assessed as
a function ofoxygen concentration using an established technique
(Franko et al, 1987). Unlabelled M006 and MOlOb tumours were
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excised and cut into roughly cubic fragments (largest dimension
2 mm) which were incubated with [3H]misonidazole in minimal
essential medium at several oxygen concentrations for 3 h at 37°C.
The only modification to the previously published methods
(Franko et al, 1987) was to incubate each fragment separately in
chambers created within the 60-mm glass Petri dishes by installing
glass partitions. This avoided clumping of the fragments on the
shaker table. Tissue fragments were fixed in formalin, embedded
in wax and sectioned, and autoradiography was used as above to
quantify the distribution of misonidazole adducts at the fragment
surface and on sections which passed near the centre ofeach frag-
ment. A grid of 10-gm squares was aligned perpendicular to the
tissue surface, and the grains in successive squares were recorded
along ten randomly chosen tracks for each oxygen level.
Additional counts over randomly chosen cells at the surface of
fragments were taken using the 10-gm squares ofthe grid.
Oxygen consumption
In order to measure oxygen consumption of monolayer cultures,
cells in exponential growth or plateau phase were trypsinized and
resuspended in complete medium. Oxygen consumption was deter-
mined using a Clark-type electrode (Koch, 1984), which measured
the oxygen concentration continuously in the cell suspension in a
specially designed spinner chamber held in a 370C water bath. To
measure the oxygen consumption rate of xenograft explants,
subcutaneous tumours were minced into 1-2 mm cubes and enzy-
matically disaggregated to single cells as previously described
(Allalunis-Turner and Siemann, 1986), washed and resuspended in
complete medium. The oxygen consumption rate was calculated
from the linear portion of the oxygen consumption curve and was
determined within the first hour after electrode stabilization.
RESULTS
Growth characteristics and histology
Of 12 early passage human glioma cell lines selected forxenograft
transplantation, only three (M006, M059K and MOlOb) success-
fully developed tumours larger than 50 mm3. The latent periods
(taken as the time to achieve a volume of 20 mm3) ranged from 6
to 14 weeks, and the doubling times thereafter were 1-2 weeks.
Sublines were derived by disaggregating these xenografted
tumours using the same techniques as had been used to derive the
original lines from biopsy material. Sublines are designated with a
terminal X, e.g. M006X. Tumours from the sublines generally
exhibited a reduced latent period of 1-2 weeks, while the subse-
quent growth rates were similar to those ofthe original xenografts.
The histological features of the diagnostic biopsy obtained from
the patients from whom these tumour cell lines were derived were
compared with the subsequently derived xenograft histologies. It
is recognized that the tumour stroma and vasculature are derived
from the SCID mouse host and that changes in histological archi-
tecture may appear on this basis. Overall, the lines investigated
appear to have reproduced some, but not all, of the features of the
original tumours. Typically, the M059K tumours showed closely
aggregated cells with prominent nuclei and mitotic activity with
rare multinuclear giant cells present. Extensive necrosis was seen
in 25% of tumours derived from the M059K line. In the M059KX
tumours, representing the second passage in vivo, the neoplastic
cells were similar in appearance, and there were wider fields of
Figure 1 Photomicrographs of histological sections from a subcutaneous
M006 tumour labelled with [3H]misonidazole in vivo. Sections are orientated
with cells displaying pyknotic nuclei at the edge of necrosis on the right side
of the image. Autoradiographic grains are dense adjacent to some necroses
(A) but appear sparse adjacent to others (B). Image size 280 gm x 200 gim
coagulation necrosis in all tumours examined, with an abrupt tran-
sition between the neoplastic cells to necrosis. No marginating
palisade of pyknotic cells was present adjacent to the necrotic
areas. Typically, the M006 tumours showed dense clusters of
polygonal cells accompanied by round or oval nuclei and minimal
intervening cytoplasm without giant cells. Mitotic activity was
infrequent. Multiple areas of necrosis were seen in all tumours of
the M006 and M006X lines, and these were not demarcated by a
peripheral palisade ofhyperchromatic necrotic neoplastic cells. In
M006 tumours growing intracranially in nude rats, a similarexten-
sive pattern ofnecrosis was seen. Finally, MOlOb tumours showed
a bimorphic pattern of polygonal and fusiform cells that were
closely cohesive. Mitotic activity was relatively infrequent.
Multiple foci of necrosis were demonstrable, and most of these
foci were accompanied by a peripheral palisade of demarcating
hyperchromatic tumour cells.
Nitroimidazole labelling of xenografts
In situ labelling ofsubcutaneous M006 tumours with [3H]misonida-
zole revealed that some necrotic regions were surrounded by dense
autoradiographic labelling, however some were notheavily labelled
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(Figure IA and B). Subcutaneous M059K tumours also show a vari-
able pattern of labelling, with roughly half of the necroses lightly
cso 160f .I A ,labelled. Incontrast,continuousheavy labellingtypically surrounds
=L j t _ I!L J f - X necroses in subcutaneous MOlOb tumours. In this tumour, some
S 140-r ) w, areas of light labelling are present but they are rare, representing
1t20 R 5-10% of regions adjacent to necrosis. In subcutaneous M006X
tumours labelled with [1251]IAZA, a very similar pattern of auto-
radiographic grain distribution was noted compared with that
found with misonidazole. Specifically, some necrotic regions were
surrounded by heavy labelling, but not all necrotic regions revealed
c so z , X w -x- 8.4 p.p.m. labelling adjacent to necrosis. There was no qualitative difference
t40L q ' 101040 p.p.m. between thebindingpatterns ofthe two nitroimidazoles. FourM006
.i 3570 p.p.m. tumours were successfully grown intracranially in nude rats, three
11720 ppm O20 o- - 98350p.p.m. of which were labelled with [3H]misonidazole. Similar to subcuta-
1 1I, 1 1, 1 ,-" j neous M006 tumours, all tumours displayed extensive necrosis at
0 50 100 150 200 250 300 autopsy. A similar pattern of labelling was noted in these intra-
Distance from surface of fragment (,um) cranial tumours, with some necroses, but not all, displaying heavily
labelled cells adjacent to necrosis.
Figure 2 Relationship of [3H]misonidazole autoradiographic grain density
measured radially across (A) M01Ob and (B) M006X tumour fragments
incubated at defined oxygen concentrations (inset) in equilibrium with the
medium. Ten tracks were scored at each oxygen level. Ninety-five per cent Nitroreductive capacity of gilomas
confidence intervals for the curves are shown Examination ofthegraindensityradially across tumourfragments
incubated with [3H]misonidazole in 10% oxygen revealed a varia-
tion from light labelling at the periphery of the fragment to heavy
Table 1 Misonidazole binding to tumour fragments in vitro in nitrogen
Tumour Misonidazole Misonidazole Exposure Observed grain Adjusted grain
concentration specific (days) density density
(gM) activity (grains per 100gm2) (grains per 100gm2)
(jci mg-,)
M006X 50 3 700 7 125 68
MOO1Ob 50 3 700 7 119 64
M0059K 10 15 600 7 189 54
RIF-1a 50 370 56 100 68
Lewis lunga 50 390 5 9 65
9Lb 100 420 3 14 110
Walker 256c 100 275 12 20 61
EMT6c 50 390 7 14 72
aUnpublished data (Franko, 1989,1994). bFranko et al (1987). cFranko et al (1992).
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Table 2 Oxygen consumption rates of human glioma cells grown in vitro and in vivo
Oxygen consumption rates(gM cell-1 h-1)a
M006 PLvalueb M01Ob P-value M059K P-value
Exponential 2.1 (±0.6) x 10-6 (6) 0.0004 2.3 (± 1.2) x 10- (4) 0.0138 1.1 (±0.5) x 10-5 (12) <0.0001
Plateau 2.2 (± 0.9) x 10-6 (3) 0.0303 2.9 (± 0.6) x 10-6 (3) <0.0001 4.3 (± 0.6) x 10-6 ( 3) 0.0121
'X' lined 2.8 (± 0.5) x 10-6 (6) <0.0001 2.5 (± 1.3) x 10-6 (3) 0.0267 9.4 (± 2.9) x 10-6 (12) <0.0001
Xenograft 7.8 (+1.7) x 10-7 (6) - 4.6 (+1.6) x 10-7c (7) - 1.6 (0.5) x 10-6 ( 2) -
aMean (± s.d.) followed by the number of measurements (in parentheses). bt-test for equality of means compared with xenograft. cDetermined for M01ObX cells.
dThe 'X' cell line designates a cell line which was established in vitro from disaggregated tumour xenografts. All 'X'-line oxygen consumption measurements
were performed on exponential phase cells.
labelling in the centre. Tumour cubes were also incubated at
several lower levels of oxygen. The dependence of grain density
upon distance from the surface ofthe tumour fragment is shown in
Figure 2. Elevated markerdensity is seen starting 150gm from the
surface ofthe MOlOb tumour fragments (Figure 2A) at the highest
oxygen concentration, reaching a maximum after 250 gm. The
binding pattern is somewhat different in the M006X fragments
(Figure 2B) where elevated density is seen starting at 70 jim at the
highest oxygen concentration, reaching a maximum at 250 ,um.
For progressively lower oxygen concentrations, the grain density
begins to rise correspondingly closer to the surface of the frag-
ment. In severe hypoxia, high grain density is seen extending to
the surface of the fragment. The relationship between misonida-
zole binding and oxygen level is shown in Figure 3, for which
additional scoring was performed at the surface of M006X and
MOlOb tumour fragments. Assessment of the M059K tumour was
not possible because lymphocytes had migrated to the surface of
fragments of this tumour. These results suggest that the bioreduc-
tive enzymes required to form nitroimidazole adducts were present
in glioma tissues and that nitroimidazole binding was oxygen
sensitive in vitro. As misonidazole binding occurs as a linear func-
tion oftime,binding rates can be calculated (Chapman et al, 1983).
The binding rates (expressed as grain densities) ofmisonidazole to
fragments oftumours ofa wide variety ofhistologies under severe
hypoxia have been compared in Table 1. Assuming that the
binding rate varies with the square root of drug concentration
under severe hypoxia (Koch et al, 1984) and correcting for differ-
ences in exposure time and specific activity, it is possible to calcu-
late an adjusted grain density. The mean adjusted grain density for
the three glioma xenografts is 62.0 ± 7.21 grains per 100 jim2,
close to the mean density of 75.2 ± 19.9 grains per 100 jm2
observed in five tumours studied previously.
Oxygen consumption
In order to determine if the ability to reduce oxygen consumption
rate in response to decreased availability ofmolecular oxygen may
be an adaptive response in gliomas, the rate ofoxygen utilization of
exponential and plateau-phase monolayers and cells freshly disso-
ciated from tumours was compared. The results shown in Table 2
indicate that glioma cell lines vary in their rate of oxygen
consumption and that glioma cells isolated from subcutaneous
xenografts from all three lines had a significantly reduced rate of
oxygen consumption, compared with that of the same line main-
tained in monolayer culture. Further, there was no significant
difference between the oxygen consumption rates of exponential
and plateau-phase monolayer cultures. The data indicate that M006
and MOlOb cells use oxygen at a rate four to fivefold less than that
of M059K cells. The cell lines derived from xenografts and main-
tained by serial passage in vitro also differ among the three glioma
sources tested. However, within each glioma series (e.g. the M006
lines), the oxygen utilization of the xenograft-derived lines main-
tained in vitro is similar to that ofthe parent cell line.
When grown as subcutaneous xenografts (Table 2), M006
xenografts consumed oxygen at a rate approximately 2.7 times
lower than that of the M006 line. M059K xenografts consumed
oxygen at a rate almost sevenfold lower than exponential M059K
monolayers. The xenograft oxygen consumption was significantly
lower in the M0106. In order to exclude the possibility that enzy-
matic disaggregation caused an artifactual lowering of oxygen
consumption, M006 monolayers were either trypsinized as usual
before measurement of oxygen concentration or treated for
1 h with the disaggregating enzyme 'cocktail' (0.025% collage-
nase, 0.05% pronase and 0.04% DNAase) (Allalunis-Turmer and
Sieman, 1986). No significant difference in oxygen consumption
was observed.
DISCUSSION
It has been reported that human gliomas contain bioreductive
enzymes [NAD(P)H-cytochrome P450 oxidoreductase, NAD(P)H
-quinone oxidoreductase] (Rampling et al, 1994), which might be
involved in the reductive activation of nitroimidazoles (Cobb et al,
1990; Parliament et al, 1992; Joseph et al, 1994). Thus, the finding
that unresected, untreated human malignant gliomas failed to show
avidity for the hypoxia marker ['231]IAZA in situ was unexpected.
Because LAZA is a lipophilic agent [log P (octanol-water) = 4], it
can theoretically be expected to cross the intact blood-brain barrier.
Further, disruption of the blood-brain barrier in deeper regions of
primary brain tumours has long been recognized, suggesting that
inadequate exposure of putative hypoxic cells in deeper regions to
nitroimidazoles is extremely unlikely. Measurements of IAZA
tumour tissue concentration would clarify this point but would be
logistically and ethically difficult toperform.
Model systems were developed to test several hypotheses for
the failure of ['231]IAZA to detect hypoxic regions in gliomas: (1)
inadequate drug delivery or intracellular uptake, (2) altered
kinetics ofnitroimidazole activation by glioma nitroreductases and
(3) development of necrosis due to depletion of substrates other
than oxygen. Previous work has established the feasibility of both
subcutaneous and intracranial sites of tumour transplantation in
immune-deficient rodents (Rana et al, 1977; Bradley et al, 1978;
Shapiro et al, 1979). The reason for using two different implanta-
tion sites was to evaluate the possibility that the intracranial
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microenvironment was unique with respect to oxygenation owing
to differences in tumour interstitial pressure, tumour blood flow
and/or vascular architecture. The adequacy of xenografted
tumours as models for human gliomas in situ deserves comment.
Previous studies predicted the development of an altered pheno-
type with repeated serial passages in mice,presumably because of
genetic instability and/or selection (Shapiro and Basler, 1979).
With serial passages, tumours may manifest altered antigenicity,
cellularity, percentage tumour take and median latent period
before palpable growth (Bullard et al, 1981; Horten et al, 1981;
Jones et al, 1981). We initiated this series of experiments with
early passage glioma cell lines and identified specific sublines
which originated after one passagethrough the animal host. In this
way, every attempt was made to study the properties of cells
closely related to the original tumour biopsy.
In situ labelling of glioma xenografts with [3H]misonidazole
and ['251]IAZA showed elevated nitroimidazole binding adjacent
to some areas of necrosis (Figure 1), in a manner which is consis-
tent with hypoxia at the edge of necrosis (Chapman et al, 1981;
Urtasun et al, 1986). This supports the notion that these drugs
encounter noproblem with diffusionthrough tumourtissue or with
intracellulartransport andbinding.Despite the obvious differences
in host species and implantation site, it is remarkable that the vari-
able association between elevated hypoxia-marker binding and
necrosis was seen both in the SCID mouse and nude rat models.
The finding of some regions of necrosis that were not heavily
labelled with [3H]misonidazole raises the possibility that in M006
and M0059K tumours, necrosis can occur despite an absence of
significant hypoxia. This contrasts with the classical finding of
heavily labelled cells uniformly surrounding necrosis in murine
tumours such as EMT-6 (Chapman et al., 1982).
In vitro, when [3H]misonidazole was incubated with glioma
tumour fragments, there was a rise in grain density with radial
distance from the surface of the fragment in a manner consistent
with the presumed oxygen gradient (Franko et al, 1987). In prin-
ciple, the steeply rising portion of the curve, which begins at the
surface at the lowest concentrations of oxygen, should be repro-
duced at progressively greater depths for incubation in greater
oxygen concentrations. This was the case for the MO1Ob tumour
(Figure 2A) and for the M006X tumour at all but the highest
oxygen concentration (Figure 2B). The gradual rise in the latter
curve could have arisen as an artifact of the shape of the tumour
fragments used, which might have allowed diffusion of oxygen in
the direction perpendicular to the plane ofthe histological section.
Alternatively, considering the size of the 95% confidence limits,
the shape ofthe curve might not be significantly different from the
theoretical expectation. It is clear from the data that, given suffi-
cient distance, both tumours were capable ofmetabolizing oxygen
to sufficiently low levels as to yield the maximal rate ofbinding of
misonidazole. The distance from the surface at which maximal
binding of nitroimidazoles occurred is within the range of
distances observed for human colon carcinomas and a melanoma
and breast carcinoma (Franko et al, 1992) and for the oxygen
diffusion distance calculated for the hypoxia probe AF-2 in the
IF.1 and ICC VII tumours Lewis lung carcinoma and WiDr human
colon carcinoma (Olive et al, 1992). In Table 1, the adjusted grain
density in glioma tumour fragments incubated under severe
hypoxia with [3H]misonidazole is very similar to that of murine
tumours for which the binding characteristics have been exten-
sively studied (Franko et al, 1987, 1992). On the basis of these
data, it would appear that intracellular uptake, the kinetics of
hypoxic activation and the binding of nitroimidazoles in human
gliomas are qualitatively similar to those observed in many animal
and human tumours.
Mammalian cells or tissues whose rate of oxygen consumption
varies with the availability of oxygen are termed 'oxygen
conformers' (Hochachka and Guppy, 1987 p. 11). In contrast, cells
or tissues whose rate of oxygen consumption is independent of
oxygen availability down to very low values are classed as
'oxygen regulators'. Normal mammalian brain functions as an
oxygen regulator (Kinter et al, 1984), whereas skeletal muscle is
classed as 'the most02 conforming ofall tissues' (Hochachka and
Guppy, 1987, p. 11). The extent to which malignantly transformed
cells retain the respiratory characteristics of the normal tissue of
origin has not been extensively investigated. We are currently
examining the possibility that glioma cells exhibit an oxygen-
conforming phenotype. Our preliminary studies with human
malignant glioma cells would suggest that the patterns of oxygen
consumption observed in tumour cells are significantly different
from that which would have been predicted based on the oxygen
consumption behaviour of normal brain. For example, the oxygen
consumption rate of M006, M059K and MO1ObX cells grown in
vivo, in whichpO2 values are unlikely to exceed 2-5%, was signif-
icantly less than the oxygen consumption rate of tumour cells
grown in vitro in which the concentration of oxygen in the
medium is near equilibrium with that of the atmosphere (18%
oxygen). As other microenvironmental factors in vivo may poten-
tially alter metabolism, it will be important to assess the extent to
which oxygen concentration per se modulates respiration. In vitro
studies measuring oxygen consumption rates ofmonolayerglioma
cultures equilibrated under different oyxgen concentrations are
currently in progress. Our preliminary results suggest that oxygen
consumption rates of these cells conform to oxygen availability
(J Allalunis-Turner,unpublished observation).
The difference in oxygen consumption rate observed between
freshly explanted tumours and monolayer cultures cannot be
attributed to a difference in the growth phase of the cells as the
oxygenconsumption rate ofplateau- andexponential-phase mono-
layer cultures was not significantly different. In addition, these
differences are unlikely to reflect loss of cell viability as oxygen
consumption rates were calculated from the trace obtained imme-
diately after electrode stabilization, within the first hour. The
possibility of metabolic changes due to the effect of disaggre-
gating enzymes has been raised (Olive et al, 1992), however we
are not aware of published data to indicate that this could poten-
tially account for the magnitude of the changes seen. Also, the
presence ofinfiltrating host cells in the tumour preparation cannot
account for the drop in oxygen utilization as histopathological
examination of tumour sections confirms that the majority of the
cells in the tumour were identical in morphology to human malig-
nant glioma cells and indeed infiltrating cells, such as tumours,
macrophages and neutrophils, themselves consume oxygen.
Thefinding ofdiminished oxygen consumption in freshly disso-
ciated explants from xenografts compared with that of monolayer
cultures suggests that, unlike normal mammalian brain, malignant
gliomas display an oxygen-conforming phenotype. This is consis-
tent with a coordinate inhibition or down-regulation ofrespiration
in glioma cells in a 3-dimensional tumour system, as suggested by
the '50-PET studies. Observations of such an effect were initially
made decades ago (Warburg, 1956), and experiments with V79
and EMT6 spheroids have shown such an effect (Freyer et al,
1984; Freyer and Sutherland, 1985). Also, necrosis has been
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observed in human glioma spheroids at relatively high central
oxygen levels as determined by microelectrodes (Carlsson et al,
1979, 1983). Ifdown-regulation ofoxygen consumption was coor-
dinated at a microregional level, it might provide an explanation
for the variable presence ofsevere hypoxia adjacent to necrosis, as
indicated by nitroimidazole binding in the xenografts. Our data
raise the possibility that for some human gliomas, as well as in
portions ofthe xenografts, necrosis may occur in many subregions
as a result ofdepletion ofglucose orother substrates, as opposed to
oxygen. If hypoxic subregions were present, these could be below
the limit of detection by SPECT imaging because of substantial
volume averaging. However, the current animal model data would
suggest that if substantial hypoxic volumes are present in gliomas
compared with extracranial tumours or brain metastases, these
regions would reasonably be expected to bind ['231]IAZA in
detectable amounts. This leads us to postulate that the use and
distribution of oxygen in human gliomas differs from extracranial
tumours and brain metastases in ways that are significant. Studies
of these potential differences may have important implications for
the use ofhypoxic cytotoxins in glioma therapy in the clinic.
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